Literature DB >> 9437823

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs.

G Bourdoiseau1, C Bonnefont, E Hoareau, C Boehringer, T Stolle, L Chabanne.   

Abstract

Peripheral blood lymphocyte subpopulations and specific IgG1 and IgG2 antibody levels were studied in 14 dogs naturally infected with Leishmania infantum using flow cytometry and ELISA. Six dogs (Group 1) were asymptomatic, and received no treatment. Samples from this group were collected from D0 to D180. The other eight dogs (Group 2) showed clinical symptoms, and were treated with Glucantime (from D0 to D40), with samples being collected from D0 to D90. Twenty-two healthy dogs were used as a control group (Group 3). The results demonstrated changes in the lymphocyte subsets, as well as a decrease in humoral and cellular immunity, in the infected dogs. Analysis of the B-cell populations of Groups 1 and 2 showed a striking reduction in the number of CD21+ cells. There was also a reduction in the CD5+, CD4+ and CD8+ T-cell populations. Drug therapy was found to partly restore the lost immunity, essentially the cell-mediated immunity. Both IgG1- and IgG2- specific antibodies were detected in sera from the fourteen infected dogs, but the IgG2 subclass appeared to be predominant. A significant decrease in the level of IgG2 antibodies was observed in treated and untreated dogs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437823     DOI: 10.1016/s0165-2427(97)00072-x

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  19 in total

1.  Ability of immunodiagnostic tests to differentiate between dogs naturally infected with Leishmania infantum and Leishmune(®)-vaccinated dogs.

Authors:  R A N Ribeiro; R G Teixeira-Neto; V S Belo; E C Ferreira; H D F H Schallig; E S Silva
Journal:  Vet Res Commun       Date:  2015-02-11       Impact factor: 2.459

2.  Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds.

Authors:  M A Dea-Ayuela; S Rama-Iñiguez; J M Alunda; F Bolás-Fernandez
Journal:  Vet Res Commun       Date:  2007-01-19       Impact factor: 2.459

3.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

4.  Evaluation of enzyme-linked immunosorbent assays, an immunofluorescent-antibody test, and two rapid tests (immunochromatographic-dipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs.

Authors:  Maik Mettler; Felix Grimm; Gioia Capelli; Heinrich Camp; Peter Deplazes
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

5.  A conventional beagle dog model for acute and chronic infection with Helicobacter pylori.

Authors:  G Rossi; M Rossi; C G Vitali; D Fortuna; D Burroni; L Pancotto; S Capecchi; S Sozzi; G Renzoni; G Braca; G Del Giudice; R Rappuoli; P Ghiara; E Taccini
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.

Authors:  A B Reis; A Teixeira-Carvalho; R C Giunchetti; L L Guerra; M G Carvalho; W Mayrink; O Genaro; R Corrêa-Oliveira; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

8.  Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano-Souza; Wendel Coura-Vital; Samuel Leôncio Braga; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Marta de Lana; Nelder Figueiredo Gontijo; Marcos José Marques; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

9.  Experimental infection of dogs with Leishmania and saliva as a model to study Canine Visceral Leishmaniasis.

Authors:  Dirceu Joaquim Costa; Rayssa M de Araujo Carvalho; Melissa Abbehusen; Clarissa Teixeira; Maiana Pitombo; Joelma Trigo; Flávia Nascimento; Lucilene Amorim; Ana Lucia Abreu-Silva; Maria do Socorro Pires Cruz; José Carlos Miranda; Kyoshi Fukutani; Camila I de Oliveira; Aldina Barral; Manoel Barral-Netto; Cláudia Brodskyn
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.